Day: August 16, 2023

All figures quoted in U.S. dollars unless otherwise noted:2023 Q2 revenue of $660 million; 931 equivalent units (“EUs”) delivered, with 25% being battery- and fuel cell-electric buses (“ZEBs”). 2023 Q2 Adjusted EBITDA2 of $12 million; Net loss of $48 million; Net loss per Share of $0.62 and Adjusted Net Loss per Share2 of $0.46. Ending liquidity2 position of $82 million, with a minimum liquidity requirement of $25 million. Ending total backlog position (both firm and options) of 9,803 EUs (valued at a record $6.7 billion2); ZEB backlog now 3,491 EUs, or 36%, of total backlog. Active North American public bid universe ended at 10,054 EUs, up 33% year-over-year; ZEBs now represent 53% of the Total Bid Universe. Updated financial guidance for Fiscal 2023 for revenue of $2.6 to $2.8 billion and Adjusted EBITDA...

Conference Call Today, August 16, 2023, at 8:30 a.m. ET FORT LAUDERDALE, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (Nasdaq: BFI, BFIIW) (“BurgerFi” or the “Company”), owner of one of the nation’s leading fast-casual “better burger” dining concepts through the BurgerFi brand, and the high-quality, casual dining pizza and wings concept under the name Anthony’s Coal Fired Pizza & Wings (“Anthony’s”) brand, today reported financial results for the second quarter ended July 3, 2023. Highlights for the Second Quarter 2023Total revenue was $43.4 million in the second quarter 2023 compared to $45.3 million in the prior year periodConsolidated systemwide sales decreased to $70.7 million compared to $74.3 million in the prior period Same-store sales growth of 1% at Anthony’s in the second quarter of 2023...

ACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced financial results for the six months ended June 30, 2023. “We continued to limit our cash burn during the quarter while executing our clinical strategy for the Symphony IL-6 test and are confident that our planned clinical and analytical studies may support a 510(k) FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients,” said Neil Dey, CEO of Bluejay Diagnostics. “We are excited to now have a clear pathway to obtain regulatory clearance of our Symphony IL-6 test, which will serve to demonstrate the vast capabilities...

Second Quarter 2023 Revenues were $37.4 Million, Representing a 59% Increase Year-over-Year; First Half 2023 Revenues of $68.2 Million, Up 32% Year-over-Year First Half 2023 Adjusted EBITDA of $9.9 Million, Up 24% Year-over-Year Robust Second Quarter Results and Positive Outlook for Second Half of 2023 Support Reiteration of Fiscal Year 2023 Revenue Guidance of $138 Million – $146 Million, and Adjusted EBITDA of $22 Million to $26 Million Extended U.S. Distribution Agreement for KEDRAB® Rabies Immunoglobulin with Kedrion Biopharma Through March 2026 Reports Positive Scientific Advice from European Medicines Agency (EMA) Regarding Ongoing Pivotal Inhaled AAT Study that Reconfirms the Overall Design of the Study and Acknowledges Certain Positive Results Demonstrated in Previously Completed Phase 2/3 Study Shareholder Vote to Approve...

Delivers Q2 Revenue of $13.2 Million, Exceeding Guidance of $12.0 Million and Representing 58% Sequential Growth PALM BEACH GARDENS, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) — Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL), a leading air purification technology company, today reported financial results for the three months (“Q2 2023”) ended June 30, 2023. Second Quarter 2023 Financial and Operational Highlights(Unless otherwise stated, comparisons are made between Q2 2023 and Q2 2022 results)Revenues were $13.2 million, an increase of 58% as compared to the first quarter of 2023. Gross profit was $4.5 million, or $5.7 million on an adjusted basis to exclude $1.2 million of costs resulting from a step up in inventory value related to purchase accounting. Gross profit margin giving effect to the adjustment was 43%. Operating...

Figure 1:Isometric view of Level 520 of the Meteysaca vein showing the location of systematic channel sampling. Individual channel samples are shown within nine zones, colour-coded according to AgEq values.Figure 2:Isometric view of Level 560 of the Perseguida vein showing the location of systematic channel sampling. Individual channel samples are shown within nine zones, colour-coded according to AgEq values.Figure 3:Location of initial four drill holes from Phase 2 of the 2023 drill programTable 3:Summary of initial results from Phase 2 drill holesFigure 4:Long section along the Perseguida vein showing initial results from Phase 2 of the 2023 drilling programFigure 5:Location of Phase 1 Pozo Rico BQ diameter drill holes.Table 4:Summary of results from previously undisclosed...